Oh of course, unless you could put in those variables.
In the case of this company, it's not really one of those types of bio's.
And the scanner only provides ideas Stoney... it doesn't push the buttons.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
In the case of this company, it's not really one of those types of bio's.
And the scanner only provides ideas Stoney... it doesn't push the buttons.
Stoney my scanner flagged TOST for earnings a long.
It was $18.50
I didn't share because you were being so negative.
It was $20 a few minutes ago.... $19.80 now
If I were you, I'd buy in.... this one could go up 30% tomorrow (up 10% now, so 20% more additional.) if the market stays where its at.
Use an AH's stop at $19.15
It was $18.50
I didn't share because you were being so negative.
It was $20 a few minutes ago.... $19.80 now
If I were you, I'd buy in.... this one could go up 30% tomorrow (up 10% now, so 20% more additional.) if the market stays where its at.
Use an AH's stop at $19.15
SHORT REPORT- CRM.
I posed this as an idea the other day.I didn't get any feedback but all CRM's clients are cutting back.
Salesforce initiated with a Sell at Guggenheim 16:38 CRM Guggenheim analyst John DiFucci initiated coverage of Salesforce with a Sell rating and $150 price target as part of a broader research note on Software names. The near-term macro weakness will likely persist for longer than most investors anticipate and even software is susceptible to macro forces, the analyst tells investors in a research note. While the company's revenue growth benefits from a massive renewal base, its New ACV is probably less than most realize, and Salesforce also spends materially more to capture new business relative to its peers, DiFucci adds.
I posed this as an idea the other day.I didn't get any feedback but all CRM's clients are cutting back.
Salesforce initiated with a Sell at Guggenheim 16:38 CRM Guggenheim analyst John DiFucci initiated coverage of Salesforce with a Sell rating and $150 price target as part of a broader research note on Software names. The near-term macro weakness will likely persist for longer than most investors anticipate and even software is susceptible to macro forces, the analyst tells investors in a research note. While the company's revenue growth benefits from a massive renewal base, its New ACV is probably less than most realize, and Salesforce also spends materially more to capture new business relative to its peers, DiFucci adds.
Stoney my scanner flagged TOST for earnings a long.
Lol -try and tweak the settings so it gives you the idea during the trading day or even better earlier in the week.
Stoney you’re the biotech guru, what’s your view that VERU hits $18 soon? Closed $16, 52W is $18.30. SIGA hit our $22 target, good play!
Now here is a idea you don't need a scanner for.
When you have thirty years experience your own mind is a scanner and this old scanner is
spitting out a name I already own-- XPOF--
My boutique fitness play that never fired after the pandemic.
Lots of Pilates stuff---
BUY HAND OVER FIST-- ! I don't know why this stk is not over $20.
Xponential Fitness raises FY22 revenue view to $211M-$221M from $201M-$211M 16:14 XPOF FY22 revenue consensus…
I am going to use this as 6 flags replacement most likely so I too will be buying.
I have to check with HF where I got in originally. ~si
When you have thirty years experience your own mind is a scanner and this old scanner is
spitting out a name I already own-- XPOF--
My boutique fitness play that never fired after the pandemic.
Lots of Pilates stuff---
BUY HAND OVER FIST-- ! I don't know why this stk is not over $20.
Xponential Fitness raises FY22 revenue view to $211M-$221M from $201M-$211M 16:14 XPOF FY22 revenue consensus…
I am going to use this as 6 flags replacement most likely so I too will be buying.
I have to check with HF where I got in originally. ~si
Ted VERU is interesting.- Thei COVID Rx is for that nasty ARDS stuff so props for that.
It's a bit distressing to read a bio firm so upbeat about "upcoming Covid season". Aren't we about done with this?
I mean the CDC today said you don't have to quarantine. Even with Covid! I swear //ass backwards.. I think it's endemic now- we are all going to get it and not as many will be critical and so the need for this product maybe not as large as everyone thinks. I don't know if this is a Meme stock (you seem to like those) I'd be somewhat careful here.
They do have a prostrate drug about to launch I'm abit more interested in that to be honest.-
From The Co-
We are currently engaged with the FDA, EMA, MHRA, and regulatory agencies in other countries to seek emergency authorization and/or expedited reviews. If authorized, we have scaled up manufacturing to meet the demands of this summer's COVID-19 surge as well as the seasonal surges that are expected in fall and winter," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru.
It's a bit distressing to read a bio firm so upbeat about "upcoming Covid season". Aren't we about done with this?
I mean the CDC today said you don't have to quarantine. Even with Covid! I swear //ass backwards.. I think it's endemic now- we are all going to get it and not as many will be critical and so the need for this product maybe not as large as everyone thinks. I don't know if this is a Meme stock (you seem to like those) I'd be somewhat careful here.
They do have a prostrate drug about to launch I'm abit more interested in that to be honest.-
From The Co-
We are currently engaged with the FDA, EMA, MHRA, and regulatory agencies in other countries to seek emergency authorization and/or expedited reviews. If authorized, we have scaled up manufacturing to meet the demands of this summer's COVID-19 surge as well as the seasonal surges that are expected in fall and winter," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru.
Always watch VRTX.
I use Vertex as my go to in accounts for general bio exposure.
And right now that bad boy is about to break out to a 52 week I believe...
certainly close.
I use Vertex as my go to in accounts for general bio exposure.
And right now that bad boy is about to break out to a 52 week I believe...
certainly close.